ClinicalTrials.gg
CompletedNCT02605915Updated Feb 5, 2020

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

A Phase 1 interventional study of Atezolizumab and Carboplatin in HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer and Locally Advanced or Early Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing atezolizumab in Breast Neoplasms — 7 open to participants now, 15 under way, 2 of them phase 3. atezolizumab · Breast Neoplasms.

Planned enrollment
15th of 39
98 · median 67
Started
2015
with 1 other
Phase 1
5 of 39
none open now
Registered
3rd of 39
by date
Lead sponsor
7 of 39
Hoffmann-La Roche

Among the 39 studies testing atezolizumab in Breast Neoplasms, this one is the 15th largest by planned enrollment, is one of 2 that started in 2015, is one of 5 in phase 1, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 39 studies testing atezolizumab in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing atezolizumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase Ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without docetaxel) or atezolizumab and trastuzumab emtansine in participants with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) and locally advanced early breast cancer (EBC), and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer.

03

Conditions studied

  • HER2-Positive Metastatic Breast Cancer
  • HER2-Negative Metastatic Breast Cancer
  • Locally Advanced or Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented -positive and HER2-negative (cohort E only) breast cancer
  • breast cancer that is measurable (Stage 1) or early breast cancer with a primary tumor size greater than (>) 2 centimeter (cm) (Stage 2)
  • (ECOG) performed status of 0, 1 or 2; 0 or 1 (cohort E only)
  • of 12 or more weeks
  • Adequate hematologic and end-organ function
  • greater than or equal to (>=) 50 percentage (%); >=55% (cohort E only)

Exclusion criteria

Exclusion Criteria:

  • Known central nervous system (CNS) disease, except for treated asymptomatic
  • Pregnancy or lactation
  • History of disease
  • Prior allogeneic stem cell or solid organ transplantation
  • Positive test for (HIV)
  • Active or
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Cohort 1A: Atezolizumab/Trastuzumab/Pertuzumab

    Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks.

    Drug: Atezolizumab · Drug: Pertuzumab · Drug: Trastuzumab

  • Experimental
    Cohort 1B: Atezolizumab/Trastuzumab emtansine 3.6 mg

    Participants will receive atezolizumab in combination with trastuzumab emtansine (3.6 mg/kg) every 3 weeks.

    Drug: Atezolizumab · Drug: Trastuzumab emtansine

  • Experimental
    Cohort 1C: Atezolizumab/Trastuzumab emtansine 3.0 mg

    Participants will receive atezolimumab in combination with trastzumab emtansine (3.0 mg/kg) every 3 weeks.

    Drug: Atezolizumab · Drug: Trastuzumab emtansine

  • Experimental
    Cohort 1D: Atezolizumab/Trastuzumab emtansine 2.4 mg

    Participants will receive atezolimumab in combination with trastzumab emtansine (2.4 mg/kg) every 3 weeks.

    Drug: Atezolizumab · Drug: Trastuzumab emtansine

  • Experimental
    Cohort 1E: Atezolizumab/ doxorubicin/ cyclophosphamide

    Participants with HER2-negative breast cancer will receive atezolizumab (every 2 weeks) in combination with doxorubicin (every 2 weeks) and cyclophosphamide for four cycles. After the completion of four cycles of combination atezolizumab /doxorubicin / cyclophosphamide, atezolizumab will be continued as a single-agent at a dose of 1200 mg every 3 weeks.

    Drug: Atezolizumab · Drug: Doxorubicin · Drug: Cyclophosphamide

  • Experimental
    Cohort 1F: Atezolizumab/Trastuzumab/Pertuzumab/ Docetaxel

    Participants will receive atezolizumab in combination with trastuzumab, pertuzumab, and docetaxel every 3 weeks.

    Drug: Atezolizumab · Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab

  • Experimental
    Cohort 2A: Atezolizumab/Trastuzumab/Pertuzumab

    Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.

    Drug: Atezolizumab · Drug: Carboplatin · Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab

  • Experimental
    Cohort 2B: Atezolizumab/Trastuzumab emtansine

    Participants will receive atezolizumab in combination with trastuzumab emtansine every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.

    Drug: Atezolizumab · Drug: Carboplatin · Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab · Drug: Trastuzumab emtansine

  • Experimental
    Cohort 2C: Safety Expansion

    Participants with HER2-positive metastatic breast cancer/unresectable locally advanced breast cancer who received prior treatment with trastuzumab and a taxane chemotherapy will receive atezolizumab in combination with trastuzumab emtansine at the dose determined from stage 1, every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.

    Drug: Atezolizumab · Drug: Trastuzumab emtansine

  • Experimental
    Cohort 2D: Safety Expansion

    Participants with HER2-positive metastatic breast cancer recently progressed on an HP containing regimen will receive atezolimumab in combination with trastuzumab and pertuzumab every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.

    Drug: Atezolizumab · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.

    Also known as: Tecentriq, RO5541267

  • Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter\*min (mg/mL\*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.

  • Docetaxel 75 mg/m\^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.

  • Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.

    Also known as: RO4368451

  • Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.

    Also known as: RO0452317

  • Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).

    Also known as: RO5304020

  • Doxorubicin will be administered at 60 mg/m\^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.

  • Cyclophosphamide will be administered at 600 mg/m\^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose Limiting Toxicities (DLT) - Cohort 1A, 1B, 1C, 1D, 1F

    Time frame: Baseline up to Day 21

  2. Percentage of Participants With DLT - Cohort 1E

    Time frame: Baseline up to Day 28

  3. Percentage of Participants With Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.0 (NCI CTCAE V4.0)

    Time frame: Baseline up to approximately 3 years

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of Atezolizumab

    Cohorts 1A, 1B, 1C, 1D, E1, 1F, 2A, 2B, 2C, 2D: 30 minutes after end of infusion on Day 1 Cycle 1 (cycle length=21 days); pre-infusion (Hour 0) on Day 1 of Cycle 1, 2, 3 (except cohort 1E), 4, 8, on Day 1 of every 8 cycles until study treatment/early discontinuation, 120 days after treatment completion/discontinuation (up to approximately 3 years)

    Time frame: Cohorts 1A, 1B, 1C, 1D, E1, 1F, 2A, 2B, 2C, 2D: pre-infusion (Hour 0), 30 minutes after end of atezolimumab infusion on Day 1 Cycle 1 (cycle length=21 days) up to approximately 3 years (detailed timeframe provided in measure description)

  2. Minimum Serum Concentration (Cmin) of Atezolizumab

    Time frame: pre-infusion (Hour 0) on Day 1 of Cycle 1, 2, 3 (except cohort 1E), 4, 8 (cycle length=21 days), on Day 1 of every 8 cycles until study treatment/early discontinuation, 120 days after treatment completion/discontinuation (up to approximately 3 years)

  3. Cmin of Trastuzumab

    Time frame: Cohorts 1A, 1F, 2A, 2D: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)

  4. Cmin of Trastuzumab Emtansine

    Time frame: Cohorts 1B, 1C, 1D, 2B, 2C: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)

  5. Cmin of Pertuzumab

    Time frame: Cohorts 1A, 1F, 2A, 2D: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)

  6. Cmin of Doxorubicin

    Time frame: Cohort 1E: at the end of doxorubicin infusion, 4 and 8 hours after doxorubicin infusion on Day 1 of Cycle 1 and 4 (cycle length=21 days)

  7. Cmin of Cyclophosphamide

    Time frame: Cohort 1E: at the end of cyclophosphamide infusion on Day 1 of Cycle 1 and 4 (cycle length=21 days), 4 and 8 hours after cyclophosphamide infusion on Day 1 of Cycle 1

  8. Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Atezolimumab

    Time frame: pre-infusion (Hour 0) on Day 1 of Cycle 1, 2, 3 (except cohort 1E), 4, 8 (cycle length=21 days), on Day 1 of every 8 cycles until study treatment/early discontinuation, 120 days after treatment completion/discontinuation (up to approximately 3 years)

  9. Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab

    Time frame: Cohorts 1A, 1F, 2A, 2D: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)

  10. Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab Emtansine

    Time frame: Cohorts 1B, 1C, 1D, 2B, 2C: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)

  11. Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Pertuzumab

    Time frame: Cohorts 1A, 1F, 2A, 2D: pre-infusion (Hour 0) on Day 1 of Cycle 1, 3 (cycle length=21 days), at study treatment/early discontinuation, 120 days after treatment completion or discontinuation (up to approximately 3 years)

  12. Number of Treatment Cycles Received

    Time frame: Baseline up to approximately 3 years

  13. Percentage of Participants With Various Dose Intensity

    Time frame: Baseline up to approximately 3 year

  14. Plasma Concentration of Doxorubicin

    Time frame: Cohort 1E: at the end of doxorubicin infusion, 4 and 8 hours after doxorubicin infusion on Day 1 Cycle 1 and 4 (cycle length=21 days)

  15. Plasma Concentration of Cyclophosphamide

    Time frame: Cohort 1E: at the end of cyclophosphamide infusion on Day 1 of Cycle 1 and 4 (cycle length=21 days), 4 and 8 hours after cyclophosphamide infusion on Day of Cycle 1

  16. Plasma Concentration of 4-Hydroxycyclophosphamide

    Time frame: Cohort 1E: at the end of cyclophosphamide infusion on Day 1 of Cycle 1 and 4 (cycle length=21 days), 4 and 8 hours after cyclophosphamide infusion on Day of Cycle 1

  17. Plasma Concentration of Docetaxel

    Time frame: Cohort 1F: at the end of docetaxel infusion, 4 and 8 hours after docetaxel infusion on Day 1 Cycle 1 and 3 (cycle length=21 days)

07

Study locations

20 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute
    Little Rock, Arkansas 72205, United States
  • Joliet oncology hematology associates
    Joliet, Illinois 60435, United States
  • Horizon Oncology Research, Inc.
    Lafayette, Indiana 47905, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Karmanos Cancer Center; Department of Oncology
    Detroit, Michigan 48201, United States
  • HCA Midwest Division
    Kansas City, Missouri 64132, United States
  • Montefiore Medical Center, Advanced Women's Health Center, Clinical Trials and Research Unit; Depart
    Bronx, New York 10461, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • St. Luke's University Health Network
    Bethlehem, Pennsylvania 18015, United States
  • Kimmel Cancer Center Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Magee Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street
    Chattanooga, Tennessee 37404, United States
  • West Clinic
    Germantown, Tennessee 38138, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Cancer Therapy and Research Center CTRC at UTHSCSA
    San Antonio, Texas 78229, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Nov 2019, 46 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 46 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2015
First posted
Nov 16, 2015
StartActual
Dec 31, 2015
Primary completionActual
Nov 13, 2019
CompletionActual
Nov 13, 2019
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02605915
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 16, 2015
Start date
Dec 31, 2015
Primary completion
Nov 13, 2019
Completion
Nov 13, 2019
Last update
Feb 5, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Docetaxel · Ado-Trastuzumab Emtansine · Doxorubicin · Cyclophosphamide

Start the discussion